Charles Mackay
About Charles Mackay
Charles Mackay is a Research Scientist II specializing in In-vivo Pharmacology and Toxicology at Tenaya Therapeutics in San Francisco, California. He has extensive experience in cardiometabolic diseases and has previously served as an Assistant Professor at The University of Tennessee Health Science Center.
Work at Tenaya Therapeutics
Charles Mackay serves as a Research Scientist II in In-vivo Pharmacology and Toxicology at Tenaya Therapeutics. He has been with the company since 2022, contributing to research efforts in San Francisco, California. His role involves leading in-vivo biology studies that focus on the efficacy of small molecular target regulators specifically in chronic heart failure.
Previous Experience at The University of Tennessee Health Science Center
Prior to his current position, Charles Mackay worked as an Assistant Professor in Physiology at The University of Tennessee Health Science Center from 2016 to 2022. During his six years in Memphis, Tennessee, he engaged in academic and research activities, contributing to the field of physiology.
Education and Expertise
Charles Mackay holds a Doctor of Philosophy (Ph.D.) in Respiratory Physiology from King's College London, where he studied from 2013 to 2016. He also earned a Master’s Degree in Molecular Medicine from the University of Glasgow in 2012 and a Bachelor of Science (BSc) (Hons) in Applied Biomedical Science from the University of the West of Scotland in 2011. His educational background supports his expertise in cardiometabolic diseases.
Research Focus and Contributions
Charles Mackay's research focuses on target discovery and validation for various conditions, including obesity, heart failure with preserved ejection fraction (HFpEF), heart failure with reduced ejection fraction (HFrEF), and fatty liver disease. He develops preclinical animal models that mimic the phenotypes of target patient groups, utilizing established disease models to demonstrate the efficacy of gene therapies and small molecules.